Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunex Enbrel Patient Starts After Jan. 1 Will Be Via Waiting List

Executive Summary

Rheumatoid arthritis patients wishing to start Wyeth/Immunex' Enbrel after Dec. 31 will be placed on a waiting list under the Enbrel Enrollment program.

You may also be interested in...



Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis

Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications

Amgen Enbrel 50 Mg Syringe Expected To Simplify Dosing For Psoriasis

Amgen expects to receive approval by year-end for an Enbrel 50 mg pre-filled syringe that could simplify dosing of the TNF inhibitor for treatment of plaque psoriasis and other indications

Amgen Enbrel Focus Includes Push For Earlier Treatment Of RA Patients

Amgen's marketing strategy for Enbrel (etanercept) includes closing the gap between diagnosis and initiation of therapy in patients with moderate rheumatoid arthritis

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel